The Global Meningococcal Vaccine Market size is expected to reach $4.5 billion by 2026, rising at a market growth of 8.5% CAGR during the forecast period. Meningococcal meningitis is a bacterial infection that is caused by gram-negative bacteria, Neisseria meningitides that includes a spectrum of infections such as bacteremia (meningococcemia), meningitis, and bacteremia pneumonia.
The meningococcal disease is very rare but is highly fatal, if left untreated, up to 50% of the patients die or get some serious complications thereafter. In meningococcal meningitis, bacteria infect the lining of the brain and spinal cord and can potentially cause large endemics as well as epidemics. The disease is transmitted from an infected person through direct contact with droplets of the throat or respiratory secretions, asymptomatic carriers can also capable of transmitting infection.
There is an increasing prevalence of various types of bacteria that cause meningococcal meningitis. The most common type of meningitis causing bacteria are A, B, C, W, Y, and type X that was more lately reported in Africa, continue to underline the criticality of more effective vaccine of meningococcal to be available in the coming years.
Over the past few decades, cases of meningitis have been increased and are one of the key factors likely to drive the market for meningococcal vaccines. According to the Centers for Disease Control and Prevention (CDC), about 1.2 million cases of meningococcal meningitis are estimated to occur worldwide every year. The government and regulatory authorities are taking initiatives to combat the increasing prevalence of meningitis are likely to drive the market growth. For example, "Defeating meningitis by 2030" was introduced in 2018 at the World Health Assembly by Eastern Mediterranean and African regions. This program is focused to develop a strategic roadmap for the prevention of meningitis by prioritizing research and improved control activities.
Based on Brand, the market is segmented into Bexsero, Trumenba, Nimenrix, Menactra, Menveo and Other Brands. The MenACWY vaccine and MenC vaccine are expected to experience swift growth during the forecast period. This is accredited to the increased adoption of these vaccines in several countries across the globe through immunization programs. Furthermore, outbreaks of meningococcal in several countries resulted in an increasing demand for meningococcal vaccines, which further boost the growth of the meningococcal vaccine market.
Based on Type, the market is segmented into Bivalent, Quadrivalent and Other Types. Quadrivalent meningococcal vaccines had the largest revenue share of the market in 2019, owing to the increased used brands like Menveo, Menactra, and Nimenrix, for this category. New vaccines are increasingly approved that will protect people against meningococcal meningitis and is expected to boost the growth of this market.
By Age Group
Based on Age Group, the market is segmented into Infants (0 to 2 years) and Children (2 years & above). The infant segment is anticipated to be the fastest-growing segment in the coming years due to the increasing incidence of meningitis among infants. According to the European Centre for Disease Prevention and Control (ECDC), IMD incidence was observed highest in infants in 2017. In Europe, there were nearly 8.2 confirmed cases per 100,000 populations in children below one year.
Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America led the market and had a significant revenue share of the market in 2019 which is followed by Europe. Favorable approvals, supportive initiatives by the government, and high investments in R&D are the major factors fueling the North American market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Pfizer, Inc., Sanofi S.A., Walvax Biotechnology Co., Ltd., Bio-Manguinhos (Oswaldo Cruz Foundation), Bio-Med Pvt. Ltd., Chongqing Zhifei Biological Products Co., Ltd., Hualan Biological Engineering, Inc., Incepta Pharmaceuticals Ltd. and Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.).
Unique Offerings from the Publisher
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free
Key Topics Covered:
Chapter 1. Market Scope & Methodology 1.1 Market Definition 1.2 Objectives 1.3 Market Scope 1.4 Segmentation 1.4.1 Global Meningococcal Vaccine Market, by Brand 1.4.2 Global Meningococcal Vaccine Market, by Type 1.4.3 Global Meningococcal Vaccine Market, by Age Group 1.4.4 Global Meningococcal Vaccine Market, by Geography 1.5 Methodology for the research
Chapter 3. Recent Developments in Meningococcal Vaccine Market
Chapter 4. Global Meningococcal Vaccine Market by Brand 4.1 Global Bexsero Market by Region 4.2 Global Trumenba Market by Region 4.3 Global Nimenrix Market by Region 4.4 Global Menactra Market by Region 4.5 Global Menveo Market by Region 4.6 Global Other Brands Market by Region
Chapter 5. Global Meningococcal Vaccine Market by Type 5.1 Global Bivalent Market by Region 5.2 Global Quadrivalent Market by Region 5.3 Global Other Types Market by Region
Chapter 6. Global Meningococcal Vaccine Market by Age Group 6.1 Global Children (2 years & above) and Adults Market by Region 6.2 Global Infants(0 to 2 years) Market by Region
Chapter 7. Global Meningococcal Vaccine Market by Region 7.1 North America Meningococcal Vaccine Market 7.2 Europe Meningococcal Vaccine Market 7.3 Asia Pacific Meningococcal Vaccine Market 7.4 LAMEA Meningococcal Vaccine Market
Chapter 8. Company Profiles 8.1 GlaxoSmithKline PLC (GSK) 8.1.1 Company Overview 8.1.2 Financial Analysis 8.1.3 Segmental and Regional Analysis 8.1.4 Research & Development Expense 8.1.5 Recent strategies and developments: 18.104.22.168 Approvals: 8.2 Pfizer, Inc. 8.2.1 Company Overview 8.2.1 Financial Analysis 8.2.2 Segmental and Regional Analysis 8.2.3 Recent strategies and developments: 22.214.171.124 Approvals: 8.3 Sanofi S.A. 8.3.1 Company Overview 8.3.2 Financial Analysis 8.3.3 Segmental and Regional Analysis 8.3.4 Research & Development Expense 8.3.5 Recent strategies and developments: 126.96.36.199 Approvals: 8.4 Walvax Biotechnology Co., Ltd. 8.4.1 Company Overview 8.5 Bio-Manguinhos (Oswaldo Cruz Foundation) 8.5.1 Company Overview 8.5.2 Recent strategies and developments: 188.8.131.52 Partnerships, Collaborations, and Agreements: 8.6 Bio-Med Pvt. Ltd. 8.6.1 Company Overview 8.7 Chongqing Zhifei Biological Products Co., Ltd. 8.7.1 Company Overview 8.8 Hualan Biological Engineering, Inc. 8.8.1 Company Overview 8.9 Incepta Pharmaceuticals Ltd. 8.9.1 Company Overview 8.10. Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.) 8.10.1 Company Overview 8.10.2 Recent strategies and developments: 184.108.40.206 Product Launches and Product Expansions: